In BCR-ABL-negative MPN cases, the downregulation of SPAG6 resulted in reduced cell proliferation and increased apoptosis rate (Mu et al., 2022; Ding et al., 2022). Here, SPAG6 is linked to myeloproliferative neoplasm.